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Abstract
Background: Bioprosthetic valve thrombosis is previously considered as an extremely rare complication which
hasn’t been systemically recognized and understood.
Case presentation: Herein, we present an unusual case of a patient manifesting with acute heart failure, secondary to
thrombus formation in a porcine aortic bioprosthesis which was implanted 11 months prior to hospitalization. Due to
the patient’s poor heart function and intraoperative findings, thrombectomy was performed. For our best knowledge,
cases of early bioprosthetic valve thrombosis presenting with acute heart failure have seldomly been reported.
Conclusion: Our study reviews predisposing factors, typical echocardiographic features and treatment for
bioprosthetic valve thrombosis and it should be considered as a reason for bioprosthetic malfunction. A combination
of clinical and echocardiographic features can help for diagnosis preoperatively. In some certain circumstances, early
reoperation can be avoided if anticoagulant therapy works.
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Backgound
Bioprosthetic valve is advantageous over mechanical valve
as its avoidance of long-term anticoagulation and low inci-
dence of thromboembolic events. As a result, biopros-
thetic valves are being implanted with ever-increasing
frequency. However, according to previous study, the
reported incidence of bioprosthetic valve thrombosis
(BPVT) on routine echocardiographic surveillance is ap-
proximately 6% [1]. Thus, once anticoagulant treatment
has been withdrawn, BPVT should be considered as a
potential cause of prosthetic malfunction. Here we present
a rare case requiring early reoperation for BPVT on aortic
position which can provide us a better understanding of
BPVT.
Case presentation
A 61-year old Chinese male presented with recurrent
chest discomfort on exertion for 3 months and one epi-
sode of presyncope on exertion one day before referred
to our hospital. 11 months ago, the patient had received
aortic valve replacement, because of congenital bicus-
pid aortic valve, with a 21-mm Hancock II porcine
bioprosthesis (Medtronic, Inc, Minneapolis, MN, USA)
implanted following the protocol provided by the
manufacturer. Postoperative transthoracic echocardiog-
raphy (TTE) showed normal function of bioprosthesis
and he made an uneventful postoperative hospital
course. The patient was discharged on 10th postopera-
tive day and was on anticoagulation therapy with
warfarin (target international normalized ratio (INR):
1.8-2.5) for 6 months. He continued to follow up at our
hospital postoperatively.
After the patient’s emergent hospitalization, full la-
boratory workups and imaging tests were performed.
Physical examination detected tachycardia, a III grade
systolic murmur in the aortic valve area and diffuse
moist rales in both lungs. Transesophageal echocardiog-
raphy (TEE) detected a severe aortic bioprosthesis sten-
osis, with a mean transvalvular gradient of 58 mmHg, a
peak velocity of 4.95 m/sec (Fig. 1a), and an aortic valve
area of about 0.6 cm2 (Fig. 1b). Left ventricular function
had also deteriorated, compared with previous TTE
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9 months ago, with an ejection fraction of 45%. The co-
agulation function test showed the INR in the target
range. The other tests, including complete blood cells,
blood chemistry, cardiac enzymes and blood gas analysis,
were unremarkable. Because of poor recognition of
BPVT, early bioprosthetic valve failure was considered
as the major reason for the increased transvalvular gra-
dient across the aortic bioprosthesis. However, the
patient remained in significant hemodynamic instability
despite of intravenous application of diuretics and ino-
tropics. Due to his progressive decompensated heart
function, a decision of emergent salvage procedure was
made after comprehensive consideration.
Intraoperatively, regular cardiopulmonary bypass
(CPB) was established after re-sternotomy. Surgical ex-
ploration of the aortic bioprosthesis revealed throm-
bosis of the three cusps on the aortic side, limiting the
opening of the valve. In addition, we noticed that the
thrombus uniformly and loosely adhered to the aortic
side of all the leaflets inducing diffuse valvular thick-
ening and resulting in restricted leaflet motion and
stenosis (Fig. 1c). In consideration of patient’s poor
heart function and loosely adhesion of thrombus,
thrombectomy, compared with redo valve replace-
ment, seemed to be the better choice which can pro-
vide shorter aortic cross-clamp time and CPB time,
less ischemic myocardial damage and a favorable
short-term prognosis. The thrombectomy was success-
fully performed (Fig. 1d) and the CPB weaning was
uneventful. Finally, the aortic cross-clamp time was
25 min and the CPB time was 41 min.
The postoperative microbiological investigation was
negative and the histopathological analysis demonstrated
thrombus composed mainly of platelets, erythrocytes and
fibrin. The patient was discharged on warfarin with a tar-
get INR of 2–2.5 for 6 months and was followed up for
over 3 years without transvalvular gradient increasing.
Discussion
Bioprosthetic valves remain a very appealing option for
patients receiving valve replacement because of the
avoidance of long-term anticoagulation. Clinically, sig-
nificant BPVT is considered extremely uncommon.
However, in an echocardiographic surveillance study,
Oliver et al. found BPVT in 10 of 161 patients (6.2%)
with evidence of bioprosthesis dysfunction suggesting
that BPVT has a higher incidence than was previously
thought. In addition, Egbe et al. identified BPVT in 46
out of 397 (11%) bioprosthetic valves explanted at Mayo
Clinic, which also suggested BPVT a more frequent
cause of bioprosthesis dysfunction than was thought. In
contrast to the misconception that BPVT is a periopera-
tive phenomenon, Egbe’s study also revealed that 65% of
all reoperations because of BPVT occurred more than
1 year after implantation, and up to 15% of these reo-
perations occurred more than 5 years [2]. Moreover, a
previous study by Brown et al. identified 8 cases of
BPVT in porcine valves in a 16-year retrospective re-
search, none of which occurred in pericardial valves [3].
Egbe’s study supported this phenomenon that porcine
valves were the most common type in BPVT, accounting
for 36 of the 46 cases (78%), while pericardial valves
Fig. 1 a, b The TEE detected an increased mean transvalvular gradient of 58 mmHg, a peak velocity of 4.95 m/sec and a restricted bioprosthesis
opening of about 0.6 cm2. c The intraoperative view of the bioprosthetic valve, with massive thrombus (in black arrow) involving all the leaflets.
d The bioprosthetic valve after thrombectomy showed smooth surface and normal function. (TEE transesophageal echocardiography)
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accounted for 8 of the 46 cases (18%). However, the
mechanism of the different occurrence of BPVT be-
tween these types of valves remains unclear.
Based on previous study, BPVT is generally associated
with predisposing factors such as low cardiac output, left
atrial dilatation, prior history of thromboembolic events,
atrial fibrillation and hypercoagulability. In this case,
however, there was a lack of apparent precipitating fac-
tors for thrombosis, as the patient had no underlying
coagulation abnormality, left atrial dilatation or atrial
fibrillation. As for low cardiac output, the patient did
present corresponding signs such as decreased tolerance
on exertion, decreased ejection fraction of 45% on TEE
and dependence on diuretics and inotropics to maintain
hemodynamic stability. But in our opinion, the low car-
diac output in this case was much more probable a clin-
ical manifestation of acute heart failure secondary to
BPVT because all the workups and imaging exams were
unremarkable during his follow-up. In addition, it can’t
be excluded that BPVT could be a consequence of the
episode of paroxysmal atrial fibrillation or a transient
bacterial endocarditis.
Preoperative diagnosis of BPVT is not easy which
need take all the clinical factors, such as clinical pres-
entation, laboratory workups and imaging exams, into
consideration. BPVT usually manifests as chronic pro-
gressive dysfunction detected on follow-up echocardi-
ography in asymptomatic or mildly symptomatic
patients. When hemodynamics is further compro-
mised, patient can present with myocardial infarction,
pulmonary edema, even cardiogenic shock and so on.
Egbe et al. have proposed a BPVT diagnostic model
based on echocardiographic characteristics, which are
a 50% increase in prosthetic gradient within 5 years of
implantation, increased cusp thickness, and abnormal
cusp mobility. The presence of all three echocardio-
graphic features reliably diagnosed BPVT with a sensi-
tivity of 72% and a specificity of 90% [2].
The optimal treatment of the BPVT deserves further
comment. Although, thrombolytic therapy is an estab-
lished first-line therapy for high-risk patients with
mechanical valve thrombosis [4, 5], the optimal treat-
ment of BPVT is still a matter of debate. Anticoagula-
tion and operative intervention is the mainstay of
treatment. Operative intervention, including redo
valve replacement and thrombectomy, can provide an
immediate hemodynamic improvement and symptom
remission. Redo valve replacement is generally consid-
ered with favorable long-term outcome while it may
be associated with a higher risk of perivalvular leakage
and a longer CPB time. However, thrombectomy, if it
can be easily performed, usually comes out with a
lower risk of perivalvular leakage and a shorter CPB
time while its long-term outcome remains unclear. In
our opinion, redo valve replacement is suggested in patients
with compensated heart function while thrombectomy is
suggested if the thrombus can be easily removed, especially
in patients with decompensated heart function. Anticoagu-
lant treatment with unfractionated heparin, which had been
reported effective by other studies, may provide an early
complete resolution of the process [6], which can reduce
the pain and cost brought from surgery. A response to
anticoagulation therapy for BPVT is usually observed
within 4–12 weeks after initiation. However, the optimal
duration for trial of anticoagulation therapy and the most
effective anticoagulation (vitamin K antagonist vs. novel
oral anticoagulant) remain unknown. In our case, given the
patient’s hemodynamic instability, we thought the patient
need early operative intervention and the intraoperative
aortic cross-clamp time and CPB time should be as short
as possible which can provide a favorable short-term prog-
nosis. Thus, thrombectomy was finally performed.
Conclusion
BPVT is an under recognized complication than was
previously thought. It may lead to rapid bioprosthesis
dysfunction. The diagnosis of BPVT remains very chal-
lenging due to a general lack of awareness of its exist-
ence. A combination of clinical and echocardiographic
features is helpful for diagnosis. It is crucial and worthy
to consider the diagnosis of BPVT before referring for
reoperation because anticoagulant therapy may work
and reverse the bioprosthesis dysfunction.
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